Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07011667 · ClinicalTrials.gov registry record · Phase 3

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

A Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.

Active
Registry status
Phase 3
Development phase
609
Enrollment target
20
Study locations

NCT07011667 is a Phase 3 study of Obesity that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 609 participants, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07011667, a Phase 3 study of Obesity, is active but no longer recruiting, sponsored by Novo Nordisk A/S.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
609 participants
Enrollment target
20
Study locations

Study Summary

This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study. Which dose of CagriSema participants will continue on is decided by chance. If participants get placebo in the main study, participants will get CagriSema in the extension study. Participants will take one injection of study medicine once a week. The study will last for about 3 years and 3 months.

Conditions Studied

Obesity

Interventions

  • DRUG CagriSema (Cagrilintide B and Semaglutide I)
  • DRUG Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)

Study Locations (20)

Florida

  • Northeast Research Institute - Fleming Island
  • Jacksonville Ctr For Clin Res - Jacksonville
  • South Broward Research LLC - Miramar
  • Florida Inst For Clin Res LLC - Orlando
  • Oviedo Medical Research, LLC - Oviedo
  • Cnt for Diab,Obes, and Metab - Pembroke Pines

California

  • FDRC - Costa Mesa
  • Linda Vista Health Care Ctr - San Diego
  • Diablo Clinical Research, Inc. - Walnut Creek

Illinois

  • Great Lakes Clinical Trials - Chicago
  • Endeavor Health - Skokie
  • Evanston Premier Hlthcr Res - Skokie

Georgia

  • Hope Clin Res & Wellness - Conyers
  • Endocrine Research Solutions - Roswell

Missouri

  • StudyMetrix Research LLC - City of Saint Peters
  • Amicis Centers of Clinical Research - St Louis

Indiana

  • Midwest Inst For Clin Res - Indianapolis

Iowa

  • Iowa Diab & Endo Res Center - West Des Moines

Michigan

  • Northern Pines Hlth Ctr, PC - Buckley

Trial Details

FieldValue
Enrollment Target 609 participants
Start Date 2025-06-03
Est. Completion 2028-10-17
Phase Phase 3

Sponsor

Novo Nordisk A/S

431 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07011667

The ClinicalTrials.gov registry entry for NCT07011667 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 609 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (26% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which CagriSema (Cagrilintide B and Semaglutide I) is the first listed.

NCT07011667 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT07011667 about?

NCT07011667 is a clinical study titled "A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term". This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get Cagr...

What is the current status of trial NCT07011667?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 609 participants. The study started on 2025-06-03. Estimated completion is 2028-10-17.

What conditions does trial NCT07011667 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT07011667?

The interventions under investigation include: CagriSema (Cagrilintide B and Semaglutide I) (DRUG), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) (DRUG).

Who is sponsoring clinical trial NCT07011667?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07011667 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.